New ctDNA assay validated for minimal residual disease monitoring across solid tumors
Skip to content
The CRC Digest
◇ RESEARCH
New ctDNA assay validated for minimal residual disease monitoring across solid tumors
The Haystack MRD assay, a tumor-informed ctDNA test that tracks patient-specific somatic mutations, has been analytically and clinically validated across 23 solid tumor types for detecting minimal residual disease at low